Nepal Considers Banning E-Cigarette Sales Due to Rising Youth Usage

Regulations by 2FIRSTS.ai
Apr.09.2024
Nepal Considers Banning E-Cigarette Sales Due to Rising Youth Usage
Nepal considers banning e-cigarette sales due to rising youth usage and concerns over health risks, reports MyRepublica.

According to a recent report by MyRepublica, the Information Officer at the Nepal Health Education, Information and Communication Center believes that Nepal may ban the sale of e-cigarettes in the future.

 

Nepal is currently facing an issue of increasing e-cigarette usage among teenagers. According to statistics, Nepal's e-cigarette imports are projected to reach 3.2 million units by 2023, with an estimated market value of 21 billion Nepalese Rupees (approximately $15.8 million USD). Despite research indicating that e-cigarette vapor is at least 95% less harmful than smoking, Nepal considers the potential harm of e-cigarettes to be on par with traditional tobacco burning, based on health concerns.

 

According to a recent survey by the Nepal Development Research Institute, 34.1% of the population in Nepal smoke, showing an increase from 31.8% in 2020.

 

Researcher Kamal Chaulagain from the Nepal Development Studies Institute believes that the increasing popularity of tobacco consumption is due to the growing prevalence of hookahs and e-cigarettes, with some users viewing them as alternatives to traditional smoking. He also calls for an increase in tobacco taxes. Jaya Kumar Gurung, the director of the Nepal Development Studies Institute, accuses the weak enforcement of anti-smoking legislation, emphasizing the lack of public awareness regarding the harmful effects of tobacco products.

 

We welcome news tips, article submissions, interview requests, or comments on this piece.

Please contact us at info@2firsts.com, or reach out to Alan Zhao, CEO of 2Firsts, on LinkedIn


Notice

1.  This article is intended solely for professional research purposes related to industry, technology, and policy. Any references to brands or products are made purely for objective description and do not constitute any form of endorsement, recommendation, or promotion by 2Firsts.

2.  The use of nicotine-containing products — including, but not limited to, cigarettes, e-cigarettes, nicotine pouchand heated tobacco products — carries significant health risks. Users are responsible for complying with all applicable laws and regulations in their respective jurisdictions.

3.  This article is not intended to serve as the basis for any investment decisions or financial advice. 2Firsts assumes no direct or indirect liability for any inaccuracies or errors in the content.

4.  Access to this article is strictly prohibited for individuals below the legal age in their jurisdiction.

 

Copyright

 

This article is either an original work created by 2Firsts or a reproduction from third-party sources with proper attribution. All copyrights and usage rights belong to 2Firsts or the original content provider. Unauthorized reproduction, distribution, or any other form of unauthorized use by any individual or organization is strictly prohibited. Violators will be held legally accountable.

For copyright-related inquiries, please contact: info@2firsts.com

 

AI Assistance Disclaimer

 

This article may have been enhanced using AI tools to improve translation and editorial efficiency. However, due to technical limitations, inaccuracies may occur. Readers are encouraged to refer to the cited sources for the most accurate information.

We welcome any corrections or feedback. Please contact us at: info@2firsts.com

U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
U.S. FDA Includes Cytisinicline for Vaping Addiction in National Priority Voucher Program, Shortens Review to 1–2 Months
The U.S. Food and Drug Administration (FDA) has added Cytisinicline, a plant-based therapy developed by Achieve Life Sciences for nicotine vaping addiction, to its new National Priority Voucher (CNPV) program. The initiative shortens drug review timelines from 10–12 months to just 1–2 months, expediting approval for treatments that address major public health needs.
Oct.20 by 2FIRSTS.ai
Opinion | Samrat Chowdhery: Tobacco Price Elasticity—A Convenient Myth?
Opinion | Samrat Chowdhery: Tobacco Price Elasticity—A Convenient Myth?
This opinion piece, submitted by Samrat Chowdhery to 2Firsts, challenges the logic of tobacco price elasticity. It argues that high taxes often harm vulnerable populations and fuel illicit markets rather than reducing smoking.
Oct.21
Singapore's four-day joint operation to investigate e-cigarettes resulted in the arrest of four e-cigarette users
Singapore's four-day joint operation to investigate e-cigarettes resulted in the arrest of four e-cigarette users
Singapore's HSA & NEA held a 4-day joint op against e-cig use in Tampines, CBD & other areas: 4 offenders (24-43) caught, fined on-site; 27 e-cigs/accessories seized. Singapore also tightened e-cig enforcement, authorizing over 5k frontline officers on Sept 9; stricter penalties took effect Sept 1—1st under-18s: S$500 (≈US$389), 18+: S$700 (≈US$545); 2nd offenders: 3-mth rehab; 3rd+: prosecution, up to S$2k (≈US$1,557). Etomidate e-cig users face harsher penalties (higher fines, rehab) & prosecu
Sep.22 by 2FIRSTS.ai
Product | HQD launches the new HQD GO in the U.S., featuring three power levels and a ~$30 price tag.
Product | HQD launches the new HQD GO in the U.S., featuring three power levels and a ~$30 price tag.
HQD has listed the disposable HQD GO on its official site and U.S. channels. The device touts 35,000 puffs, three power levels with adjustable airflow, and a 30 mg/ml nicotine strength. On U.S. retail websites, it’s priced at about $29.99.
Oct.24 by 2FIRSTS.ai
ceshi1111
ceshi1111
Trusted by industry leaders and innovators, ARAC brings unmatched expertise in Modules 5 & 6, including label and claim development, comprehension testing, human factors/usability, and clinical-behavioral research such as actual use and switching studies. These studies generate the robust, real-world evidence needed to evaluate whether products are “Appropriate for the Protection of Public Health” (APPH) -- including randomized experimental longitudinal, actual use, cohort st
Oct.21
Product | Magnetic-attach design + mini display: FASTA’s new product goes on sale in the U.S., priced around $16
Product | Magnetic-attach design + mini display: FASTA’s new product goes on sale in the U.S., priced around $16
FASTA’s 40K Kit hits U.S. retailers: magnetic prefilled pods + reusable battery, mini display, two power levels; rated 20 mL/40,000 puffs/50 mg; some listings at $15.99.
Oct.15 by 2FIRSTS.ai